- Department for International Development
- Document Type:
- Journal Article
- McDermott, A.B., Wilson, A.J., Parks, C.L., Boggiano, C., Cassamasa, H. Chiuchiolo, M.J., Coleman, J.W., Dean, H.J., Felber, B.K., Ginsberg, A.A., Hudgens, M.G., Kemelman, M., King, C.R., Lin, F., Lopez, M., McBride, D., Morrow, G., Mullen, K., Narpala, S., Ouellett, I., Pavlakis, G.N., Sardesai, N.Y., Schultz, A., Winstone, N., Wu, D., and Zamb, T.J.
DNA priming has previously shown to elicit augmented immune responses when administered by electroporation (EP) or co-delivered with plasmid encoding IL12 (pIL-12). We hypothesized that the efficacy of a DNA prime and recombinant Adenovirus 5 boost vaccination regimen (DNA/rAd5) would be improved when incorporating these vaccination strategies into the DNA priming phase, as determined by pathogenic SIVmac239 challenge outcome. The whole SIVmac239 proteome was delivered in 5 separate DNA plasmids (pDNA-SIV) by EP with or without pIL12, followed by boosting 4 months later with corresponding rAd5-SIV vaccine vectors. Remarkably, after repeated low dose SIVmac239 mucosal challenge, we demonstrate a 2.6 and 4.4 log reduction of median SIV peak and set-point viral load in rhesus macaques (RMs) that received pDNA-SIV by EP with pIL12 compared to mock immunized controls (p
Journal of Virology (2011) [doi:10.1128/JVI.05060-11] JVI Accepts, published online ahead of print on 6 July 2011
Document Type: Journal Article
Authors: McDermott, A.B. Wilson, A.J. Parks, C.L. Boggiano, C. Cassamasa, H. Chiuchiolo, M.J. Coleman, J.W. Dean, H.J. Felber, B.K. Ginsberg, A.A. Hudgens, M.G. Kemelman, M. King, C.R. Lin, F. Lopez, M. McBride, D. Morrow, G. Mullen, K. Narpala, S. Ouellett, I. Pavlakis, G.N. Sardesai, N.Y. Schultz, A. Winstone, N. Wu, D. Zamb, T.J.